Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: EXEL
  • CUSIP: 30161Q10
Key Metrics:
  • Previous Close: $15.31
  • 50 Day Moving Average: $11.87
  • 200 Day Moving Average: $7.56
  • 52-Week Range: $3.55 - $15.46
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -153.10
  • P/E Growth: 1.00
  • Market Cap: $3.53B
  • Outstanding Shares: 230,325,000
  • Beta: 2.14
Profitability:
  • Net Margins: -265.24%
  • Return on Assets: -45.53%
Debt:
  • Debt-to-Equity Ratio: -1.55%
  • Current Ratio: 1.83%
  • Quick Ratio: 1.82%
Additional Links:
Companies Related to Exelixis:

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $11.67 (23.80% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2016Leerink SwannReiterated RatingOutperform$12.00View Rating Details
9/15/2016Stifel NicolausBoost Price TargetBuy$12.00 -> $15.00View Rating Details
9/15/2016William BlairReiterated RatingOutperformView Rating Details
8/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details
8/4/2016Piper Jaffray Cos.Reiterated RatingNeutral$5.00 -> $8.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.27)($0.24)($0.26)
Q2 20162($0.29)($0.28)($0.29)
Q3 20162($0.11)($0.07)($0.09)
Q4 20162($0.04)($0.02)($0.03)
Q1 20171$0.00$0.00$0.00
Q2 20171($0.01)($0.01)($0.01)
Q3 20171$0.01$0.01$0.01
Q4 20171$0.04$0.04$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.90%
Institutional Ownership Percentage: 81.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Exelixis (NASDAQ:EXEL)
DateHeadline
News IconAnalysts Valuations For Two Stocks: Exelixis, Inc. (NASDAQ:EXEL), Pitney Bowes Inc. (NYSE:PBI) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 26 at 5:03 PM
News IconOverbuying Activity: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL)
postregistrar.com - September 26 at 5:03 PM
smarteranalyst.com logoStock Update (NASDAQ:EXEL): Exelixis, Inc. Announces Collaborator Daiichi Sankyo's Initiation of Phase 3 Clinical ... - Smarter Analyst (NASDAQ:EXEL)
www.smarteranalyst.com - September 26 at 5:03 PM
biz.yahoo.com logoEXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:EXEL)
biz.yahoo.com - September 26 at 5:03 PM
businesswire.com logoExelixis Elects Julie Anne Smith to Its Board of Directors - Business Wire (press release) (NASDAQ:EXEL)
www.businesswire.com - September 26 at 9:40 AM
News IconStock under Radar: eBay Inc. (NASDAQ:EBAY), Exelixis, Inc ... - Newburgh Press (NASDAQ:EXEL)
newburghpress.com - September 26 at 9:40 AM
publicnow.com logoExelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist (NASDAQ:EXEL)
www.publicnow.com - September 26 at 9:40 AM
publicnow.com logoExelixis Elects Julie Anne Smith to Its Board of Directors (NASDAQ:EXEL)
www.publicnow.com - September 26 at 9:40 AM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Exelixis (EXEL) (NASDAQ:EXEL)
finance.yahoo.com - September 26 at 9:40 AM
cnbc.com logoCramer: I overstayed my welcome on this stock (NASDAQ:EXEL)
www.cnbc.com - September 23 at 4:43 PM
News IconNews review of 2 biotech stocks: Novavax, Inc. (NASDAQ:NVAX), Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 22 at 10:30 AM
News IconAnalysts Chime In On Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL)
postregistrar.com - September 22 at 10:30 AM
finance.yahoo.com logo4:56 pm Exelixis will provide update on CABOzantinib in clinical data oral presentation at the ESMO Congress on Oct 10 at 10:30am ET (previously scheduled for Oct 8) (NASDAQ:EXEL)
finance.yahoo.com - September 22 at 10:30 AM
News Icon2 Biotech Stocks News And Price Trends: Exelixis, Inc. (NASDAQ:EXEL), Galena Biopharma, Inc. (NASDAQ:GALE) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 21 at 5:26 PM
News IconOverbuying Alert on: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL)
postregistrar.com - September 21 at 5:26 PM
businesswire.com logoExelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress (NASDAQ:EXEL)
www.businesswire.com - September 21 at 9:09 AM
News IconHC Stocks in Hub! Exelixis, Inc. (EXEL), Johnson & Johnson (NYSE:JNJ) - share market updates (press release) (NASDAQ:EXEL)
sharemarketupdates.com - September 20 at 8:47 AM
News IconAnalysts Valuations For Two Stocks: Genworth Financial Inc (NYSE:GNW), Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 20 at 8:47 AM
smarteranalyst.com logoWilliam Blair Dives in on Exelixis, Inc. (EXEL) Ahead of Phase II CABOSUN Data - Smarter Analyst (NASDAQ:EXEL)
www.smarteranalyst.com - September 18 at 9:34 AM
bidnessetc.com logoExelixis, Inc. (EXEL) Stock Soars to 10-Year High After CABOMETYX Approval (NASDAQ:EXEL)
www.bidnessetc.com - September 16 at 4:49 PM
News IconExelixis Inc reiterated as Buy By Stifel Nicolaus (NASDAQ:EXEL)
larampadinapoli.com - September 16 at 4:49 PM
smarteranalyst.com logoWilliam Blair Dives in on Exelixis, Inc. (EXEL) Ahead of Phase II CABOSUN Data (NASDAQ:EXEL)
www.smarteranalyst.com - September 16 at 4:49 PM
istreetwire.com logoStocks In Action: Exelixis, Inc. (EXEL), Cliffs Natural Resources Inc. (CLF), Sysco Corporation (SYY) - iStreetWire (NASDAQ:EXEL)
istreetwire.com - September 15 at 5:20 PM
News IconBiotech news that matter for investors: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Exelixis, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 15 at 5:20 PM
News IconStock Grabbing Investor's Attention: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL)
postregistrar.com - September 15 at 5:20 PM
finance.yahoo.com logoWill Exelixis (EXEL) Continue to Surge Higher? (NASDAQ:EXEL)
finance.yahoo.com - September 15 at 5:20 PM
News IconStocks Tossing up on Optimistic Data: Exelixis, Inc. (NASDAQ:EXEL), Agilent Technologies, Inc. (NYSE:A) - Street Wise Report (press release) (blog) (NASDAQ:EXEL)
streetwisereport.com - September 15 at 5:04 AM
investopedia.com logoExelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL) (NASDAQ:EXEL)
www.investopedia.com - September 14 at 10:08 PM
News IconEuropean Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following... (NASDAQ:EXEL)
ih.advfn.com - September 14 at 5:01 PM
streetinsider.com logoExelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy (NASDAQ:EXEL)
www.streetinsider.com - September 14 at 5:01 PM
investopedia.com logoExelixis Shares Soar on Cancer Therapies (EXEL) (NASDAQ:EXEL)
www.investopedia.com - September 14 at 5:01 PM
finance.yahoo.com logoEuropean Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy (NASDAQ:EXEL)
finance.yahoo.com - September 14 at 5:01 PM
marketwatch.com logoExelixis, Ipsen say EU approves kidney cancer drug (NASDAQ:EXEL)
www.marketwatch.com - September 14 at 5:01 PM
smarteranalyst.com logoStock Update (NASDAQ:EXEL): Exelixis, Inc.’s CABOMETYX Approved by the European Commission for the Treatment of Advanced Renal Cell Carcinoma (NASDAQ:EXEL)
www.smarteranalyst.com - September 14 at 5:01 PM
investors.com logoBevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar (NASDAQ:EXEL)
www.investors.com - September 14 at 5:01 PM
News IconHC Stocks Updates= Unilife Corp (UNIS), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:EXEL)
sharemarketupdates.com - September 14 at 9:06 AM
smarteranalyst.com logoStock Update (NASDAQ:EXEL): Exelixis, Inc.'s CABOMETYX Approved by the European Commission for the Treatment ... - Smarter Analyst (NASDAQ:EXEL)
www.smarteranalyst.com - September 14 at 9:06 AM
seekingalpha.com logoExelixis' Cabometyx approved in Europe for kidney cancer; shares up 1% premarket (NASDAQ:EXEL)
seekingalpha.com - September 14 at 7:53 AM
News IconAnalysts Taking Ride on Hard Facts For- Exelixis, Inc. (NASDAQ:EXEL), Catalent, Inc. (NYSE:CTLT) - Seneca Globe (NASDAQ:EXEL)
www.senecaglobe.com - September 11 at 4:39 PM
News IconTop Earnings to Watch for: Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 9 at 4:49 PM
News IconAnalysts Advise About Exelixis, Inc. (NASDAQ:EXEL) - National Daily Press (NASDAQ:EXEL)
www.nationaldailypress.com - September 9 at 4:49 PM
News IconIntraday Active Biotech Stocks News: Exelixis, Inc. (NASDAQ:EXEL ... - The Voice Registrar (NASDAQ:EXEL)
voiceregistrar.com - September 9 at 4:49 PM
smarteranalyst.com logoStock Update (NASDAQ:EXEL): Exelixis, Inc. Announces Outcome from First ... (NASDAQ:EXEL)
www.smarteranalyst.com - September 9 at 9:45 AM
News IconHC Stocks Alerts= Esperion Therapeutics Inc (ESPR), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:EXEL)
sharemarketupdates.com - September 8 at 8:48 AM
fool.com logoThe Clear Reason Behind Exelixis, Inc.'s 21% Gain in August - Motley Fool (NASDAQ:EXEL)
www.fool.com - September 8 at 8:48 AM
247wallst.com logoKey FDA Decisions and Trial Results Expected in October (NASDAQ:EXEL)
247wallst.com - September 8 at 8:48 AM
fool.com logoThe Clear Reason Behind Exelixis, Inc.'s 21% Gain in August (NASDAQ:EXEL)
www.fool.com - September 8 at 8:48 AM
News IconBiotechnology Stocks to Lookout: Navidea Biopharmaceuticals Inc (NYSEMKT: NAVB), Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar (NASDAQ:EXEL)
postregistrar.com - September 7 at 5:04 PM
News IconInsider Trading Activity: Exelixis, Inc. (NASDAQ:EXEL) - Post Registrar - Post Registrar (NASDAQ:EXEL)
postregistrar.com - September 7 at 8:17 AM
smarteranalyst.com logoStock Update (NASDAQ:EXEL): Exelixis, Inc. Announces Outcome from First Planned Interim Analysis of the Phase 3 ... - Smarter Analyst (NASDAQ:EXEL)
www.smarteranalyst.com - September 7 at 8:17 AM

Social

Exelixis (NASDAQ:EXEL) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff